From: Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review
Mutation | Positive/ total cases | Prevalence (%) | Reference |
---|---|---|---|
BRAF V600E | 0/7 | 0 | [51] |
 | 2/6 | 33 | [52] |
 | 3/29 | 10 | [53] |
 | 2/10 | 20 | [54] |
 | 8/16 | 50 | [55] |
 | 0/4 | 0 | [56] |
 | 6/17 | 35 | [57] |
Overall BRAFV600E | 21/89 | 23 | Â |
RAS | 4/50 | 8 | [44] |
 | 2/18 | 11 | [58] |
 | 1/5 | 20 | [59] |
 | 4/18 | 23 | [43] |
 | 15/29 | 55 | [60] |
 | 4/50 | 8 | [61] |
 | 3/5 | 60 | [62] |
Overall RAS mutations | 33/162 | 20 | Â |
RET/PTC | 0/14 | 0 | [63] |
 | 3/51 | 6 | [44] |
 | 0/17 | 0 | [64] |
Overall RET/PTC | 3/81 | 4 | Â |